Your browser doesn't support javascript.
loading
Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported Outcomes.
Younossi, Zobair M; Stepanova, Maria; Jacobson, Ira; Muir, Andrew J; Pol, Stanislas; Zeuzem, Stefan; Younes, Ziad; Herring, Robert; Lawitz, Eric; Younossi, Issah; Racila, Andrei.
Afiliación
  • Younossi ZM; Center for Liver Diseases, Department of Medicine.
  • Stepanova M; Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia.
  • Jacobson I; Center for Outcomes Research Liver Diseases, Washington, DC.
  • Muir AJ; New York University Langone Health.
  • Pol S; Duke Clinical Research Institute, Durham, North Carolina.
  • Zeuzem S; Hopital Cochin, Universite Paris Descartes, France.
  • Younes Z; Universitatsklinikum, Frankfurt, Germany.
  • Herring R; Gastro One, Germantown.
  • Lawitz E; Quality Medical Research, Nashville, Tennessee.
  • Younossi I; Texas Liver Institute, University of Texas Health, San Antonio.
  • Racila A; Center for Outcomes Research Liver Diseases, Washington, DC.
Clin Infect Dis ; 70(4): 628-632, 2020 02 03.
Article en En | MEDLINE | ID: mdl-30949674
ABSTRACT

BACKGROUND:

The causative relationship between the clearance of infections and long-term, health-related quality-of-life (HRQL) improvements in patients with hepatitis C virus (HCV) has been generally accepted. The aim of this study was to assess long-term HRQL trends in HCV patients who did not achieve sustained virologic responses (SVRs) after treatment with direct-acting antivirals.

METHODS:

HCV patients who completed treatment in clinical trials and did not achieve SVRs were enrolled in a long-term registry (#NCT01457768). HRQL scores were prospectively collected using the short form-36 instrument (8 HRQL domains and 2 summary scores).

RESULTS:

There were 242 patients included they had a median age of 54 years (standard deviation ± 8 years), 85% were male, and 38% had cirrhosis. Before treatment, patients' HRQL scores were similar to the general population norms (all 1-sided P > 0.05), but were followed by significant decreases by the end of treatment (-3.4 to -6.2 points; P < .05 for 5/8 HRQL domains and mental summary). By the time subjects entered the registry, all but 1 of the mean HRQL scores had returned to their pretreatment levels (P > .05). During subsequent periods in the registry, patients experienced further HRQL decrements up to -9.2 points (P < .05 for all HRQL domains) at Week 24 and up to -8.3 points (P < .05 for 5/8 HRQL domains) at Week 48. Although these HRQL decrements were observed regardless of cirrhosis status, they were more pronounced in patients with cirrhosis (P < .05 for 3/8 HRQL domains).

CONCLUSIONS:

Patients who did not achieve an SVR after treatment experienced worsening HRQL scores in long-term follow-ups. Retreatment of these patients will be important not only to improve their clinical outcomes, but also their quality of life.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antivirales / Hepatitis C Crónica Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antivirales / Hepatitis C Crónica Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2020 Tipo del documento: Article